ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

Key Takeaways Untreated sleep apnea contributes to car crashesPatients who got no treatment were 21% more likely to be in a ...

Mouth taping offers sleep benefits but has some potential risks. Learn how to mouth-tape safely and other options to reduce ...

A cat named Lottie might have taken things a step too far when she wasn't getting the attention she wanted. Instead of ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people ...

Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) machine ... and allows a person to keep breathing during sleep. However, it is undeniable ...